The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.
 
Rachel H. Giles
Honoraria - Merck KGaA
Travel, Accommodations, Expenses - Ipsen; Merck KGaA
 
Deb Maskens
Honoraria - BMS Canada; Merck
Consulting or Advisory Role - Pfizer
 
Robin Martinez
No Relationships to Disclose
 
Karin Kastrati
Honoraria - MorphoSys
Consulting or Advisory Role - Bayer (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Carlos Castro
No Relationships to Disclose
 
Juan Carlo Julian Mauro
Expert Testimony - Astellas Oncology (Inst); AstraZeneca (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Baxter (Inst); Bristol-Myers Squibb (Inst); Diaverum (Inst); Vifor Pharma (Inst)
 
Robert Bick
No Relationships to Disclose
 
Malcolm Packer
No Relationships to Disclose
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
James Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kymab; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Secarna; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Eric Jonasch
Consulting or Advisory Role - aravive; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer
Research Funding - Aravive; Novartis; Peloton Therapeutics
Travel, Accommodations, Expenses - Pfizer
 
Sara Jane Maclennan
No Relationships to Disclose
 
Michael A.S. Jewett
No Relationships to Disclose